Dual-color HIV reporters trace a population of latently infected cells and enable their purification

Virology

Volumn 446, Issue 1-2, 2013, Pages 283-292

  Calvanese, Vincenzo ^a,c   Chavez, Leonard ^a,c   Laurent, Timothy ^b,d   Ding, Sheng ^b,d   Verdin, Eric ^a,c  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FLUORESCENT DYE; RED FLUORESCENT PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL SEPARATION; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PURIFICATION; REPORTER GENE; VIRUS LATENCY; VIRUS REACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; STAINING AND LABELING; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84884526443     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.07.037     Document Type: Article

References (29)

1. Archin N.M., Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
2. (+) T cells. Nat. Med. 2012, 18:1682-1687.
3. + T cells. PLoS Pathog. 2011, 7:e1002288.
4. + T cells. Blood 2009, 113:58-65.
5. Carter C.C., Onafuwa-Nuga A., McNamara L.A., Riddell J.t., Bixby D., Savona M.R., Collins K.L. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 2010, 16:446-451.
6. Colin L., Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009, 6:111.
7. Contreras X., Schweneker M., Chen C.S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284:6782-6789.
8. Cummins N.W., Badley A.D. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis. 2010, 1:e99.
9. Dahabieh M.S., Ooms M., Simon V., Sadowski I. A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J. Virol. 2013, 87:4716-4727.
10. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 2011, 62:141-155.
11. Duverger, A., Wolschendorf, F., Zhang, M., Wagner, F., Hatcher, B., Jones, J., Cron, R.Q., van der Sluis, R.M., Jeeninga, R.E., Berkhout, B., Kutsch, O., 2012. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J. Virol.
12. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., Beddows S., Weber J., Sharp P.M., Shaw G.M., Hahn B.H. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization. J. Virol. 1996, 70:1651-1667.
13. Gozlan J., Lathey J.L., Spector S.A. Human immunodeficiency virus type 1 induction mediated by genistein is linked to cell cycle arrest in G2. J. Virol. 1998, 72:8174-8180.
14. Hakre S., Chavez L., Shirakawa K., Verdin E. Epigenetic regulation of HIV latency. Curr. Opin. HIV AIDS 2011, 6:19-24.
15. Hakre S., Chavez L., Shirakawa K., Verdin E. HIV latency: experimental systems and molecular models. FEMS Microbiol Rev. 2012, 36:706-716.
16. Jordan A., Bisgrove D., Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003, 22:1868-1877.
17. Krishnan V., Zeichner S.L. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J. Virol. 2004, 78:9458-9473.
18. Lassen K.G., Hebbeler A.M., Bhattacharyya D., Lobritz M.A., Greene W.C. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 2012, 7:e30176.
19. Li M.Z., Elledge S.J. SLIC: a method for sequence- and ligation-independent cloning. Methods Mol. Biol. 2012, 852:51-59.
20. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 1998, 338:853-860.
21. Pierson T.C., Zhou Y., Kieffer T.L., Ruff C.T., Buck C., Siliciano R.F. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 2002, 76:8518-8531.
22. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J.S., Quivy V., Vanhulle C., Lamine A., Vaira D., Demonte D., Martinelli V., Veithen E., Cherrier T., Avettand V., Poutrel S., Piette J., de Launoit Y., Moutschen M., Burny A., Rouzioux C., De Wit S., Herbein G., Rohr O., Collette Y., Lambotte O., Clumeck N., Van Lint C Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009, 4:e6093.
23. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
24. Shaner N.C., Lin M.Z., McKeown M.R., Steinbach P.A., Hazelwood K.L., Davidson M.W., Tsien R.Y. Improving the photostability of bright monomeric orange and red fluorescent proteins. Nat. Methods 2008, 5:545-551.
25. Sirven A., Ravet E., Charneau P., Zennou V., Coulombel L., Guetard D., Pflumio F., Dubart-Kupperschmitt A. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol. Ther. 2001, 3:438-448.
26. Trono D., Van Lint C., Rouzioux C., Verdin E., Barre-Sinoussi F., Chun T.W., Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180.
27. Weinberger L.S., Dar R.D., Simpson M.L. Transient-mediated fate determination in a transcriptional circuit of HIV. Nat. Genet. 2008, 40:466-470.
28. Williams S.A., Chen L.F., Kwon H., Fenard D., Bisgrove D., Verdin E., Greene W.C. Prostratin antagonizes HIV latency by activating NF-kappaB. J. Biol. Chem. 2004, 279:42008-42017.
29. Yang H.C., Xing S., Shan L., O'Connell K., Dinoso J., Shen A., Zhou Y., Shrum C.K., Han Y., Liu J.O., Zhang H., Margolick J.B., Siliciano R.F. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 2009, 119:3473-3486.